The Theoretical Case Is Strong. The Clinical Evidence Is Absent. Psilocybin promotes neuroplasticity, and neuroplasticity is exactly what the post-concussion brain needs. Psilocybin (and its active metabolite psilocin) activates the 5-HT2A serotonin receptor, which triggers a cascade of intracellular signaling that increases brain-derived neurotrophic factor (BDNF), promotes dendritic growth, strengthens synaptic connections, and enhances neural circuit reorganization. These are the biological processes that resolve post-concussion syndrome: the brain needs to form new connections, strengthen damaged pathways, and reorganize circuits around injured areas (Ly et al., 2018). Psilocybin also reduces neuroinflammation through modulation of the immune response. Persistent post-concussion syndrome involves chronic low-grade neuroinflammation that impairs recovery. Anti-inflammatory effects at the neural level are directly therapeutic for this pathology. The serotonergic modulation addresses the mood and anxiety symptoms common in persistent post-concussion syndrome. The default mode network disruption psilocybin produces breaks rigid neural patterns associated with chronic symptom states. The problem: none of this has been tested in concussion patients. The neuroplasticity data comes from rodent studies and cell cultures. The clinical data on psilocybin for depression, PTSD, and anxiety comes from non-concussion populations. Extrapolating these findings to post-concussion syndrome is scientifically reasonable but clinically unvalidated. We do not know the optimal dose, timing, frequency, or risk profile for concussion-specific application. Anecdotal reports are encouraging but are subject to placebo effects and selection bias. What Microdosing Is and Is Not A microdose is a sub-perceptual dose: enough to affect neural chemistry without producing a psychedelic experience. Typical microdoses are 50-200mg of dried psilocybin mushrooms (approximately 1-3mg of psilocybin), taken every 3-4 days. At this dose, users do not experience visual effects, altered perception, or impaired function. The goal is the neuroplasticity and anti-inflammatory effects without the psychoactive experience. Microdosing is not a macro-dose. Full psychedelic doses (2-5 grams of dried mushrooms) produce profound altered states that carry different risks for the concussed brain. The sensory amplification, emotional intensity, and cognitive disruption of a full dose stress a brain that is already overwhelmed by normal sensory processing. Full-dose psilocybin in the context of concussion is a different risk-benefit calculation than microdosing. This article addresses microdosing specifically. The Stamets Protocol is the most commonly referenced microdosing schedule: psilocybin mushrooms with lion's mane mushroom and niacin (vitamin B3), taken on a 4-days-on, 3-days-off cycle. Lion's mane has independent evidence for nerve growth factor stimulation. Niacin produces peripheral vasodilation that theoretically improves delivery to extremities. The combined protocol is popular in the post-concussion community but has not been studied in any clinical trial. Potential Benefits for Post-Concussion Syndrome Neuroplasticity enhancement. The primary theoretical benefit. BDNF increase, dendritic growth, and synaptic strengthening are the mechanisms the post-concussion brain needs for circuit repair. If microdosing produces these effects at sub-perceptual doses (which laboratory studies suggest it does), it would support the biological recovery process (Ly et al., 2018). Neuroinflammation modulation. Persistent post-concussion symptoms correlate with ongoing neuroinflammation. Psilocybin's anti-inflammatory effects at the 5-HT2A receptor reduce inflammatory cytokine production and modulate microglial activation. Reducing chronic neuroinflammation removes a key barrier to symptom resolution. Default mode network reset. Persistent post-concussion syndrome involves maladaptive neural patterns: the brain gets stuck in symptom-reinforcing loops. Psilocybin disrupts default mode network rigidity, potentially allowing the brain to break free from these patterns. This mechanism is best established for depression but is theoretically applicable to the ruminative, catastrophizing patterns common in chronic post-concussion syndrome. Mood and anxiety improvement. Depression and anxiety are common in persistent post-concussion syndrome and independently slow recovery. Psilocybin's established efficacy for treatment-resistant depression and anxiety (at full doses) suggests that even microdoses provide mood support that facilitates overall recovery. Potential Risks and Concerns Serotonin syndrome risk with concurrent medications. If you take SSRIs, SNRIs, trazodone, or MAOIs for post-concussion symptoms, combining them with psilocybin creates serotonin syndrome risk. Serotonin syndrome is a medical emergency characterized by agitation, hyperthermia, muscle rigidity, and seizures. At microdose levels, this risk is low but not zero. Do not combine psilocybin with serotonergic medications without medical guidance. Seizure threshold concerns. Psilocybin affects cortical excitability. The post-concussion brain already has altered excitability. While clinical seizures from psilocybin microdoses are not reported in the literature, the theoretical interaction exists and has not been studied in concussion populations specifically. Cardiovascular effects in a dysregulated autonomic system. Psilocybin produces mild increases in heart rate and blood pressure. For post-concussion patients with autonomic dysfunction, these cardiovascular effects interact with an already-unstable system. POTS patients and those with significant orthostatic intolerance should exercise additional caution. Psychological vulnerability. Even at microdose levels, psilocybin affects mood and perception. Post-concussion patients with anxiety, depression, or PTSD are processing these conditions with a damaged brain. Amplifying emotional processing (even mildly) in a brain with reduced prefrontal regulation introduces unpredictable psychological effects. Legal status. Psilocybin remains a Schedule I controlled substance in most jurisdictions. Possession and use carry legal consequences that add stress (counterproductive to recovery) and limit access to quality-controlled products (increasing risk of contamination, incorrect dosing, or misidentified species). Supporting Neuroplasticity Through Proven Methods Whether or not you explore psilocybin, these exercises promote the neuroplasticity and autonomic regulation that post-concussion recovery requires. JME 1 Slow cervical rotation with extended exhale breathing promotes neuroplasticity through the combination of novel movement patterns and parasympathetic activation. Exercise is the most proven neuroplasticity enhancer. BDNF increases with physical activity regardless of psilocybin use. 10 repetitions, performed consistently to build the neural pathways that support recovery. JME 14 Chin tucks challenge the neuromuscular system in ways that promote motor learning and proprioceptive plasticity. The isometric hold demands neural adaptation that strengthens cervical control circuits. For post-concussion syndrome where cervical motor control is persistently impaired, this exercise provides targeted neuroplastic stimulus to the circuits that need it most. JME 153 Thoracic extension with diaphragmatic breathing increases BDNF through the combined effects of postural challenge and deep breathing. The breathing component increases cerebral blood flow and oxygenation, which supports the metabolic demands of neuroplastic change. The vagal stimulation modulates neuroinflammation through the cholinergic anti-inflammatory pathway. These are the same mechanisms psilocybin targets, achieved through movement and breathing. JME 3 Lateral cervical flexion provides novel sensory input to the cervical proprioceptive system. Varied movement patterns promote broader neural adaptation than repetitive single-direction exercises. The combination of all four cervical directions (rotation, flexion, extension, lateral flexion) provides the movement diversity that maximizes neuroplastic stimulus. Start your 14-day free trial for neuroplasticity-promoting recovery routines. Additional Recovery Support JME 42 Shoulder mobility challenges the upper kinetic chain in patterns that promote neural adaptation. Movement variety is a key driver of neuroplasticity. Adding shoulder mobility to cervical exercises increases the breadth of neural circuits being stimulated and strengthened. JME 150 Thoracic rotation provides vestibular-proprioceptive integration training. The rotational movement challenges the brain to integrate sensory inputs from the vestibular system, cervical proprioceptors, and visual system simultaneously. This multisensory integration is a neuroplastic process that improves with practice. JME 5 Cervical extension mobilizes the craniocervical junction, which influences cerebrospinal fluid dynamics. The glymphatic system that clears neuroinflammatory debris depends on cerebrospinal fluid flow. Optimizing craniocervical mobility supports the waste clearance that reduces the neuroinflammation psilocybin theoretically targets. JME 6 Cervical flexion before sleep optimizes the sleep quality that is essential for neuroplasticity. Sleep is when the brain consolidates the neural changes stimulated during the day. Whether those changes were stimulated by exercise, psilocybin, or both, sleep is required to solidify them. Protecting sleep quality through pre-sleep cervical mobility maximizes the neuroplastic benefit of any intervention. Promote neuroplasticity through movement with simplmobility's structured programming. Should I tell my doctor I am microdosing? Yes. Your concussion specialist needs to know about all substances you are taking to provide safe, effective care. Psilocybin interacts with medications and affects the symptoms they are monitoring. A specialist who knows you are microdosing accounts for its effects in their assessment. Legal concerns about disclosure are understandable, but the medical conversation is protected by patient-provider confidentiality. Your doctor cannot report personal drug use to law enforcement. When is microdosing most appropriate during concussion recovery? If microdosing has a role in concussion recovery, it is during the persistent (chronic) phase, not the acute phase. The first 2-4 weeks after concussion involve active neurometabolic crisis where introducing additional neurochemical modulation adds risk without established benefit. Persistent post-concussion syndrome (symptoms lasting beyond 3 months despite standard treatment) is where the theoretical benefits of neuroplasticity enhancement, neuroinflammation reduction, and default mode network reset are most relevant. What is the evidence that microdosing works for anything? Controlled studies on microdosing are limited. The largest placebo-controlled microdosing study (Szigeti et al., 2021) found that microdosing improved mood and creativity measures, but the effects did not exceed placebo when participants were properly blinded. Laboratory studies confirm that sub-perceptual doses of psilocybin produce measurable neuroplastic changes (BDNF increase, dendritic growth) in animal models. The disconnect between objective neural changes and subjective benefit in blinded studies suggests the effects are real but subtle, and expectation plays a significant role in perceived benefit. References Ly, C., et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182. PubMed Szigeti, B., et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife, 10, e62878. PubMed